One controversy aired in numerous sessions and hallways at this year’s American Association for Cancer Research annual meeting was the future of proteomic patterns in cancer diagnosis. Can protein “signatures,” generated by mass spectrometers, accurately and reliably distinguish cancer from noncancer?